Genomics is at an inflection point. Dramatic declines in sequencing costs and significant advances in our understanding of the genome means we’re moving closer to a world where genomics is the standard of care. Evidence is emerging that population-level screening drives meaningful clinical impact with ~1 in 30 people having an actionable result, but up to 90% of them are missed under current guidelines. Leading health systems are working to solve this by offering broad genetic screening to their communities. But questions remain about how to handle results when millions of people are screened. The tools and services to enable this are critical, including patient- and physician-friendly results, educational materials, and genetic counseling. In this session, healthcare leaders will discuss how they scale return of results and improve outcomes for their communities.
Biography
Justin is a co-founder and SVP of Business Development & Strategy at Helix, a population genomics company with a mission to empower every person to improve their life through DNA. Helix’s end-to-end population health solution enables health systems to integrate genomic information on a population scale to improve outcomes, lower costs, increase patient engagement, and accelerate research. Prior to Helix, Justin was a Vice President in the healthcare group at Warburg Pincus, a global private equity firm focused on growth investing. Earlier in his career, he also spent time at the Boston Consulting Group, where he worked with a variety of companies in the tech and healthcare industries, and Onyx Pharmaceuticals. Justin holds a B.S. in Chemical Engineering and a M.S. in Bioengineering from Stanford University. He also received a J.D. from Stanford Law School and an M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
Biography
Trained in human genetics, Dr. Willard’s career in entrepreneurial leadership in academia and healthcare has provided a foundation of experience and expertise at the intersection of genetics, genomics, and healthcare. In late 2017, he established Geisinger National as an outward-looking unit of Geisinger Health for clinically inspired research and implementation of genomic medicine, working with genomics companies, universities, medical centers, and health systems around the country. As part of decade-long efforts in genomics and medicine at Geisinger, the Geisinger team of scientists and health professionals have brought population genomics to the front lines of population-based healthcare. To build on this foundation, he and members of the Geisinger National team are now transitioning away from Geisinger to move to the commercial health sector.
Biography
Teresa Kruisselbrink is the Genetic Counselor Supervisor in the Mayo Clinic Center for Individualized Medicine. She began her career in 1997 at Mayo Clinic by establishing the role of the laboratory-based genetic counselor in Molecular Genetics, Biochemical Genetics, Cytogenetics, and Maternal Serum Screening. She has provided genetic counseling in Medical Genetics, Neurology, Obstetrics, Cardiology and outreach clinics. Ms. Kruisselbrink contributes to numerous educational programs including Mayo Medical School, Graduate School, and fellowship and residency programs in the laboratory and clinical environments. She is also actively involved in mentoring high school and college students wishing to pursue a career in genetic counseling. Teresa received her BS in Molecular, Cellular, Developmental Biology, and Genetics and MS in Genetic Counseling from the University of Minnesota. She is an Instructor of Laboratory Medicine and Pathology.
Biography
Cassie Hajek is a Sioux Falls, SD native. She graduated from the University of South Dakota Sanford School of Medicine and completed Internal Medicine residency at Montefiore Medical Center in Bronx NY. Prior to completing medical genetics fellowship at the UCLA Intercampus Medical Genetics Program, she practiced outpatient internal medicine at Sanford Adult Medicine in Sioux Falls. Her training was focused on Adult Genetics and the genetics of common complex disease and genomic contribution to risk. Since completing her training in June 2016, she has been a leader in the development of Sanford Health’s preemptive genetic screening program. This has included the design and launch of a system-wide education and return of results program. She is committed to identifying new approaches to integrating genetics and genomics in the care of patients and currently serves as the physician chair and medical director for the Sanford Imagenetics program.